Karim Sleiman1, Malini Veerappan1, Katrina P Winter1, Michelle N McCall1, Glenn Yiu2, Sina Farsiu3, Emily Y Chew4, Traci Clemons5, Cynthia A Toth6. 1. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina. 2. Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California. 3. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina; Department of Biomedical Engineering, Duke University, Durham, North Carolina. 4. National Eye Institute, National Institutes of Health, Bethesda, Maryland. 5. The Emmes Corporation, Rockville, Maryland. 6. Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina; Department of Biomedical Engineering, Duke University, Durham, North Carolina. Electronic address: cynthia.toth@dm.duke.edu.
Abstract
PURPOSE: Appearance of geographic atrophy (GA) on color photography (CP) is preceded by specific features on spectral-domain optical coherence tomography (SD OCT). We aimed to build SD OCT-based risk assessment models for 5-year new onset of GA and central GA on CP. DESIGN: Prospective, longitudinal study. PARTICIPANTS: Age-Related Eye Disease Study 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral large drusen or noncentral GA and at least 1 eye without advanced disease (n = 317). METHODS: For 1 eye per participant, qualitative and quantitative SD OCT variables were derived from standardized grading and semiautomated segmentation, respectively, at baseline. Up to 7 years later, annual outcomes were extracted and analyzed to fit multivariate logistic regression models and build a risk calculator. MAIN OUTCOME MEASURES: New onset of CP-visible GA and central GA. RESULTS: Over a follow-up median of 4.0 years and among 292 AMD eyes (without advanced disease at baseline) with complete outcome data, 46 (15.8%) developed central GA. Among 265 eyes without any GA on baseline CP, 70 (26.4%) developed CP-visible GA. Final multivariate models were adjusted for age. In the model for GA, the independent predicting SD OCT factors (P < 0.001-0.03) were: hyperreflective foci and retinal pigment epithelium (RPE) layer atrophy or absence, followed by choroid thickness in absence of subretinal drusenoid deposits, photoreceptor outer segment loss, RPE drusen complex volume, and RPE drusen complex abnormal thinning volume. For central GA, the factors (P < 0.001) were RPE drusen complex abnormal thinning volume, intraretinal fluid or cystoid spaces, hyperreflective foci, and RPE layer atrophy or absence. The models yielded a calculator that computes the probabilities of CP-visible, new-onset GA and central GA after 1 to 5 years. CONCLUSIONS: For AMD eyes with large drusen and no advanced disease, we built a novel risk assessment model-based on age and SD OCT segmentation, drusen characteristics, and retinal pathology-for progression to CP-visible GA over up to 5 years. This calculator may simplify SD OCT grading and with future validation has a promising role as a clinical prognostic tool.
RCT Entities:
PURPOSE: Appearance of geographic atrophy (GA) on color photography (CP) is preceded by specific features on spectral-domain optical coherence tomography (SD OCT). We aimed to build SD OCT-based risk assessment models for 5-year new onset of GA and central GA on CP. DESIGN: Prospective, longitudinal study. PARTICIPANTS: Age-Related Eye Disease Study 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral large drusen or noncentral GA and at least 1 eye without advanced disease (n = 317). METHODS: For 1 eye per participant, qualitative and quantitative SD OCT variables were derived from standardized grading and semiautomated segmentation, respectively, at baseline. Up to 7 years later, annual outcomes were extracted and analyzed to fit multivariate logistic regression models and build a risk calculator. MAIN OUTCOME MEASURES: New onset of CP-visible GA and central GA. RESULTS: Over a follow-up median of 4.0 years and among 292 AMD eyes (without advanced disease at baseline) with complete outcome data, 46 (15.8%) developed central GA. Among 265 eyes without any GA on baseline CP, 70 (26.4%) developed CP-visible GA. Final multivariate models were adjusted for age. In the model for GA, the independent predicting SD OCT factors (P < 0.001-0.03) were: hyperreflective foci and retinal pigment epithelium (RPE) layer atrophy or absence, followed by choroid thickness in absence of subretinal drusenoid deposits, photoreceptor outer segment loss, RPE drusen complex volume, and RPE drusen complex abnormal thinning volume. For central GA, the factors (P < 0.001) were RPE drusen complex abnormal thinning volume, intraretinal fluid or cystoid spaces, hyperreflective foci, and RPE layer atrophy or absence. The models yielded a calculator that computes the probabilities of CP-visible, new-onset GA and central GA after 1 to 5 years. CONCLUSIONS: For AMD eyes with large drusen and no advanced disease, we built a novel risk assessment model-based on age and SD OCT segmentation, drusen characteristics, and retinal pathology-for progression to CP-visible GA over up to 5 years. This calculator may simplify SD OCT grading and with future validation has a promising role as a clinical prognostic tool.
Authors: Joo Yong Lee; Francisco A Folgar; Maureen G Maguire; Gui-shuang Ying; Cynthia A Toth; Daniel F Martin; Glenn J Jaffe Journal: Ophthalmology Date: 2014-07-23 Impact factor: 12.079
Authors: Kristin J Meyers; Zhe Liu; Amy E Millen; Sudha K Iyengar; Barbara A Blodi; Elizabeth Johnson; D Max Snodderly; Michael L Klein; Karen M Gehrs; Lesley Tinker; Gloria E Sarto; Jennifer Robinson; Robert B Wallace; Julie A Mares Journal: Ophthalmology Date: 2015-09-06 Impact factor: 12.079
Authors: Giovanni Gregori; Fenghua Wang; Philip J Rosenfeld; Zohar Yehoshua; Ninel Z Gregori; Brandon J Lujan; Carmen A Puliafito; William J Feuer Journal: Ophthalmology Date: 2011-03-09 Impact factor: 12.079
Authors: Manpreet Brar; Igor Kozak; Lingyun Cheng; Dirk-Uwe G Bartsch; Ritchie Yuson; Nitin Nigam; Stephen F Oster; Francesca Mojana; William R Freeman Journal: Am J Ophthalmol Date: 2009-07-09 Impact factor: 5.258
Authors: Francisco A Folgar; Jessica H Chow; Sina Farsiu; Wai T Wong; Stefanie G Schuman; Rachelle V O'Connell; Katrina P Winter; Emily Y Chew; Thomas S Hwang; Sunil K Srivastava; Molly W Harrington; Traci E Clemons; Cynthia A Toth Journal: Invest Ophthalmol Vis Sci Date: 2012-07-09 Impact factor: 4.799
Authors: Tiarnan D Keenan; Elvira Agrón; Amitha Domalpally; Traci E Clemons; Freekje van Asten; Wai T Wong; Ronald G Danis; SriniVas Sadda; Philip J Rosenfeld; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frederick L Ferris; Emily Y Chew Journal: Ophthalmology Date: 2018-07-27 Impact factor: 12.079
Authors: Benjamin S Echols; Mark E Clark; Thomas A Swain; Ling Chen; Deepayan Kar; Yuhua Zhang; Kenneth R Sloan; Gerald McGwin; Ramya Singireddy; Christian Mays; David Kilpatrick; Jason N Crosson; Cynthia Owsley; Christine A Curcio Journal: Ophthalmol Retina Date: 2020-05-07
Authors: Malini Veerappan Pasricha; Vincent Tai; Karim Sleiman; Katrina Winter; Stephanie J Chiu; Sina Farsiu; Sandra S Stinnett; Eleonora M Lad; Wai T Wong; Emily Y Chew; Cynthia A Toth Journal: Ophthalmol Retina Date: 2020-12-22
Authors: Bryan M Wong; Richard W Cheng; Efrem D Mandelcorn; Edward Margolin; Sherif El-Defrawy; Peng Yan; Anna T Santiago; Elena Leontieva; Wendy Lou; Wendy Hatch; Christopher Hudson Journal: Transl Vis Sci Technol Date: 2019-09-11 Impact factor: 3.283
Authors: Avni P Finn; Maxwell Pistilli; Vincent Tai; Ebenezer Daniel; Gui-Shuang Ying; Maureen G Maguire; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Cynthia A Toth Journal: Am J Ophthalmol Date: 2020-11-19 Impact factor: 5.258